Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pharmacokinetic Comparability Study of a Commercial Supply of Eptinezumab

Trial Profile

A Pharmacokinetic Comparability Study of a Commercial Supply of Eptinezumab

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Acronyms ALD403-CLIN-014
  • Most Recent Events

    • 23 Oct 2018 Results published in the Alder Biopharmaceuticals Media Release
    • 23 Oct 2018 According to an Alder Biopharmaceuticals Media Release,Status changed from planning to completed.
    • 20 Mar 2018 According to an Alder BioPharmaceuticals media release, this study is anticipated to complete in in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top